Anzeige
Mehr »
Login
Sonntag, 29.11.2020 Börsentäglich über 12.000 News von 646 internationalen Medien
Lithium und Kupfer explodieren! Tesla warnte bereits vor Engpässen! Diese Kupfer-Aktie hat 194% Upside!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
44 Leser
Artikel bewerten:
(0)

AMDL Launches Updated Web Site


TUSTIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- AMDL, Inc. , developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has launched a redesigned Company web site at http://www.amdl.com/ . The new web site includes detailed information about the Company's new acquisition, Jade Pharmaceutical, Inc. in China, and includes a link to Jade Pharmaceutical's web site.

The updated web site carefully details AMDL's products, facilities, management team, its management commitments and vision, and links to research about its unique cancer test kit, the DR-70(R), and news and investor relations information about the Company.

"The updated web site reflects the Company's significantly expanded global presence with the recent acquisition of Jade Pharmaceutical, and highlights AMDL's emergence as an international manufacturing, marketing and sales company," said Gary Dreher, AMDL CEO. "We look forward to continually updating shareholders through our web site on our progress and accomplishments."

About AMDL

AMDL, Inc. , headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Gary L. Dreher President & CEO (714) 505-4460

Kostenloser Wertpapierhandel auf Smartbroker.de
© 2006 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.